MHRA-100365-PIP01-21

Key Facts

Active Substance
Active Substance:
  • Batiraxcept
Invented Name
Not yet available
PIP Number MHRA-100365-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • All pharmaceutical forms
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of Ovarian cancer
  • Treatment of Fallopian tube cancer
  • Treatment of Primary peritoneal cancer
Route(s) of administration
Route(s) of administration:
  • All routes of administration
PIP applicant
  • Kinesys Consulting Limited
  • Country United Kingdom
  • Tel 01418990081
  • Email jgould@aravive.com
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Batiraxcept.pdf
Published Date 07/12/2022